These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 39077820)

  • 1. Effect of magnesium oxide or citrate supplements on metabolic risk factors in kidney stone formers with idiopathic hyperoxaluria: a randomized clinical trial.
    Taheri M; Jalali S; Borumandnia N; Tavasoli S; Basiri A; Taheri F
    Magnes Res; 2024 Jul; 37(1):12-21. PubMed ID: 39077820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Urinary saturation and risk factors for calcium oxalate stone disease based on spot and 24-hour urine specimens.
    Ogawa Y; Yonou H; Hokama S; Oda M; Morozumi M; Sugaya K
    Front Biosci; 2003 Sep; 8():a167-76. PubMed ID: 12957883
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enteric hyperoxaluria secondary to small bowel resection: use of computer simulation to characterize urinary risk factors for stone formation and assess potential treatment protocols.
    Rodgers AL; Allie-Hamdulay S; Jackson GE; Sutton RA
    J Endourol; 2014 Aug; 28(8):985-94. PubMed ID: 24773381
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Urinary lithogenic risk profile in recurrent stone formers with hyperoxaluria: a randomized controlled trial comparing DASH (Dietary Approaches to Stop Hypertension)-style and low-oxalate diets.
    Noori N; Honarkar E; Goldfarb DS; Kalantar-Zadeh K; Taheri M; Shakhssalim N; Parvin M; Basiri A
    Am J Kidney Dis; 2014 Mar; 63(3):456-63. PubMed ID: 24560157
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dietary treatment of urinary risk factors for renal stone formation. A review of CLU Working Group.
    Prezioso D; Strazzullo P; Lotti T; Bianchi G; Borghi L; Caione P; Carini M; Caudarella R; Ferraro M; Gambaro G; Gelosa M; Guttilla A; Illiano E; Martino M; Meschi T; Messa P; Miano R; Napodano G; Nouvenne A; Rendina D; Rocco F; Rosa M; Sanseverino R; Salerno A; Spatafora S; Tasca A; Ticinesi A; Travaglini F; Trinchieri A; Vespasiani G; Zattoni F;
    Arch Ital Urol Androl; 2015 Jul; 87(2):105-20. PubMed ID: 26150027
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of crystallization risk formulas in pediatric calcium stone-formers.
    Sikora P; Zajaczkowska M; Hoppe B
    Pediatr Nephrol; 2009 Oct; 24(10):1997-2003. PubMed ID: 19333626
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in urinary parameters after oral administration of potassium-sodium citrate and magnesium oxide to prevent urolithiasis.
    Kato Y; Yamaguchi S; Yachiku S; Nakazono S; Hori J; Wada N; Hou K
    Urology; 2004 Jan; 63(1):7-11; discussion 11-2. PubMed ID: 14751336
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduction of renal stone risk by potassium-magnesium citrate during 5 weeks of bed rest.
    Zerwekh JE; Odvina CV; Wuermser LA; Pak CY
    J Urol; 2007 Jun; 177(6):2179-84. PubMed ID: 17509313
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simple dietary advice targeting five urinary parameters reduces urinary supersaturation in idiopathic calcium oxalate stone formers.
    Sromicki J; Hess B
    Urolithiasis; 2020 Oct; 48(5):425-433. PubMed ID: 32524204
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic Profile of Calcium Oxalate Stone Patients with Enteric Hyperoxaluria and Impact of Dietary Intervention.
    Siener R; Ernsten C; Welchowski T; Hesse A
    Nutrients; 2024 Aug; 16(16):. PubMed ID: 39203825
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Age, Body Mass Index, and Gender Predict 24-Hour Urine Parameters in Recurrent Idiopathic Calcium Oxalate Stone Formers.
    Otto BJ; Bozorgmehri S; Kuo J; Canales M; Bird VG; Canales B
    J Endourol; 2017 Dec; 31(12):1335-1341. PubMed ID: 29084490
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of sodium bicarbonate upon urinary citrate excretion in calcium stone formers.
    Pinheiro VB; Baxmann AC; Tiselius HG; Heilberg IP
    Urology; 2013 Jul; 82(1):33-7. PubMed ID: 23602798
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospective Randomized Evaluation of Idiopathic Hyperoxaluria Treatments.
    Gupta M; Gallante B; Bamberger JN; Khusid JA; Parkhomenko E; Chandhoke R; Capodice J; Atallah W
    J Endourol; 2021 Dec; 35(12):1844-1851. PubMed ID: 34254834
    [No Abstract]   [Full Text] [Related]  

  • 14. Magnesium, citrate, magnesium citrate and magnesium-alkali citrate as modulators of calcium oxalate crystallization in urine: observations in patients with recurrent idiopathic calcium urolithiasis.
    Schwille PO; Schmiedl A; Herrmann U; Fan J; Gottlieb D; Manoharan M; Wipplinger J
    Urol Res; 1999 Apr; 27(2):117-26. PubMed ID: 10424393
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized, controlled trial of lactic acid bacteria for idiopathic hyperoxaluria.
    Goldfarb DS; Modersitzki F; Asplin JR
    Clin J Am Soc Nephrol; 2007 Jul; 2(4):745-9. PubMed ID: 17699491
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Magnesium Decreases Urine Supersaturation but Not Calcium Oxalate Stone Formation in Genetic Hypercalciuric Stone-Forming Rats.
    Li Q; Krieger NS; Yang L; Asplin J; Bushinsky DA
    Nephron; 2024; 148(7):480-486. PubMed ID: 38262368
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early changes of oxalate and calcium urine excretion in those with calcium oxalate stone formation after extracorporeal shock wave lithotripsy.
    Oehlschläger S; Albrecht S; Hakenberg OW; Schrödter S; Froehner M; Manseck A; Wirth MP
    Urology; 2003 Jul; 62(1):17-21. PubMed ID: 12837412
    [TBL] [Abstract][Full Text] [Related]  

  • 18. What treatments reduce kidney stone risk in patients with bowel disease?
    Bianco J; Chu F; Bergsland K; Coe F; Worcester E; Prochaska M
    Urolithiasis; 2022 Oct; 50(5):557-565. PubMed ID: 35976425
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in urinary stone risk factors in hypocitraturic calcium oxalate stone formers treated with dietary sodium supplementation.
    Stoller ML; Chi T; Eisner BH; Shami G; Gentle DL
    J Urol; 2009 Mar; 181(3):1140-4. PubMed ID: 19152919
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phenotypic expression of primary hyperoxaluria: comparative features of types I and II.
    Milliner DS; Wilson DM; Smith LH
    Kidney Int; 2001 Jan; 59(1):31-6. PubMed ID: 11135054
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.